2. Search Result
Search Result
Results for "

IgG autoantibodies

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

3

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147305
    Efgartigimod alfa

    ARGX-113

    		 Fc Receptor (FcR) Inflammation/Immunology
    Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
    Efgartigimod alfa
  • HY-W020658
    L-α-Phosphatidylinositol
    1 Publications Verification

    		 HIV Infection
    L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection .
    L-α-Phosphatidylinositol
  • HY-P991611
    ART5803

    		iGluR Inflammation/Immunology
    ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
    ART5803
  • HY-P99952
    Ripertamab

    SCT400

    		 CD20 Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
    Ripertamab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: